title: A clinical and molecular review of inverted papilloma of the urinary tract: how to handle?
abstract: Inverted papilloma (IP) of the urinary tract is classified by the World Health Organisation as a non-invasive urothelial tumour with normal to minimal cytological atypia of the neoplastic cells. During the 1980s, it came under suspicion of having a premalignant or malignant potential and of being concurrent with urothelial cell carcinoma (UCC). This quandary has been proven difficult to solve, due to the fact that IP is very rare and literature mostly consists of case reports with varying levels of information, making strong meta-analyses problematic. New immunohistochemical techniques and genetic approaches are more frequently being used in the attempt to achieve better classifications, prognosis and treatment of lesions hereunder IP. This review will, in our awareness, be the first to combine the knowledge from retrospective studies with these new approaches for determining a possible premalignant potential and concurrency with UCC and subsequently outline a recommendation for follow-up.
authors.affiliation: Department of Urology, Bispebjerg and Frederiksberg Hospitals, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Peter Hjorth
authors.initials: PH
authors.lastname: Jørgensen
authors.affiliation: Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Ben
authors.initials: B
authors.lastname: Vainer
authors.affiliation: Department of Urology, Bispebjerg and Frederiksberg Hospitals, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Gregers Gautier
authors.initials: GG
authors.lastname: Hermann
mesh_terms: D002295:Carcinoma, Transitional Cell / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D002352:Carrier Proteins / Q000378:metabolism; D057167:Claudins / Q000378:metabolism; D005260:Female; D011905:Genes, ras; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D019656:Loss of Heterozygosity; D008297:Male; D008840:Microfilament Proteins / Q000378:metabolism; D009154:Mutation; D018308:Papilloma, Inverted / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D011379:Prognosis; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000235:genetics; D059506:Telomere Shortening; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D014571:Urologic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D049951:X Chromosome Inactivation
chemical_list: D002352:Carrier Proteins; D057167:Claudins; C502658:FSCN1 protein, human; D019394:Ki-67 Antigen; D008840:Microfilament Proteins; C496365:FGFR3 protein, human; D051498:Receptor, Fibroblast Growth Factor, Type 3
keywords: Inverted papilloma; urinary bladder; urinary bladder neoplasms